Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-Cell Transcriptomic Analysis of Kaposi Sarcoma

ABSTRACT: Single-Cell Transcriptomic Analysis of Kaposi Sarcoma

PROVIDER: PRJNA1168592 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-Cell Transcriptomic Analysis of Kaposi Sarcoma

Project description:Single-Cell Transcriptomic Analysis of Kaposi Sarcoma

| PRJNA1168591 | ENA

Oncogenome of Kaposi sarcoma

Project description:Oncogenome of Kaposi sarcoma

| PRJNA1213892 | ENA

Oncogenome of Kaposi sarcoma

Project description:Oncogenome of Kaposi sarcoma

| PRJNA1213891 | ENA

Transcription profiling of human lymphatic endothelial cells response to Kaposi-sarcoma herpesvirus

Project description:Assessment of the effect of Kaposi-sarcoma herpesvirus upon the transcriptome of lymphatic endothelial cells and its contribution to the transcriptome of Kaposi sarcoma.

2006-10-23 | E-MEXP-561 | biostudies-arrayexpress

Transcription profiling of Kaposi sarcoma, normal skin and primary cells

Project description:Identification of the relationships of Kaposi sarcoma (KS), normal skin to various cell cultures. The effects of KS herpes virus, the infectious cause of KS, on infected endothelial cells are also investigated.

2004-08-01 | E-MEXP-66 | biostudies-arrayexpress

Immunization of mice with virus-like vesicles of Kaposi sarcoma-associated herpesvirus reveals a role of ORF4 in complement-mediated neutralization

Project description:The development of a prophylactic vaccine for Kaposi sarcoma-associated Herpesvirus (KSHV) would prevent consequences from infection including disorders such as Kaposi sarcoma and primary effusion lymphoma. Here, we study the immunogenicity of noninfectious virus-like vesicles (VLVs) of KSHV as a potential future vaccine platform. VLVs present a repertoire of viral structural proteins but are noninfectious due to a defect in capsid formation that prevents viral DNA packaging. Immunization of mice with adjuvanted VLVs results in virus-specific antibodies and T cells. These antibodies neutralize viral infection, and this neutralization is enhanced by the complement system. Complement-enhanced neutralization is dependent on antibodies targeting the SCR region of viral ORF4. However, this activity was not present in serum from KSHV-infected humans. Our study highlights an important role of antibody effector functions in the development of a future KSHV vaccine

2023-02-01 | PXD035478 | Pride

Kaposi sarcoma exome

Project description:Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Kaposi sarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes

| EGAS00001000032 | EGA

Whole exome sequencing of biopsies of Kaposi sarcoma lesions

Project description:Whole exome sequencing of biopsies of Kaposi sarcoma lesions

| PRJNA914036 | ENA

Spatial and Bulk Transcriptomics Analyses Reveal Distinct Gene Expression Profiles in Archival Skin Kaposi Sarcoma Lesions Based on Disease Characteristics (NCounter Data)

Project description:Targeted transcriptomics assay of immuno-oncology genes using NanoString PanCancer IO 360 panel (770 gene) was carried out with archival skin Kaposi sarcoma samples. 42 participants with HIV-associated KS with and without other KSHV-associated diseases (KICS, PEL and/or MCD) included

2026-03-17 | GSE315398 | GEO

Single-cell transcriptomic profiling of 16 synovial sarcoma tumors

Project description:Single-cell transcriptomic profiling of 16 synovial sarcoma tumors

| PRJEB100841 | ENA